Grail Inc
NASDAQ:GRAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Grail Inc
NASDAQ:GRAL
|
US |
Grail Inc
Grail is a healthcare diagnostics company that develops blood tests for finding cancer signals early, before symptoms appear. Its best-known product is a multi-cancer early detection test that analyzes fragments of DNA in a blood sample to look for signs of cancer and, in some cases, suggest where in the body the signal may be coming from. The company sells these tests to doctors, health systems, employers, and, in some cases, consumers through medical channels. Grail makes money mainly by selling tests and by building clinical evidence and testing programs that can be used in screening and preventive care. Its business sits between traditional lab testing and oncology: it is not treating cancer, but trying to change how cancer is found in the first place. What makes Grail different is that it is focused on a new category of screening rather than a standard lab menu. Its value depends on getting doctors, payers, and health systems to trust that a blood test can help catch hard-to-detect cancers earlier and fit into routine care.
Grail is a healthcare diagnostics company that develops blood tests for finding cancer signals early, before symptoms appear. Its best-known product is a multi-cancer early detection test that analyzes fragments of DNA in a blood sample to look for signs of cancer and, in some cases, suggest where in the body the signal may be coming from.
The company sells these tests to doctors, health systems, employers, and, in some cases, consumers through medical channels. Grail makes money mainly by selling tests and by building clinical evidence and testing programs that can be used in screening and preventive care. Its business sits between traditional lab testing and oncology: it is not treating cancer, but trying to change how cancer is found in the first place.
What makes Grail different is that it is focused on a new category of screening rather than a standard lab menu. Its value depends on getting doctors, payers, and health systems to trust that a blood test can help catch hard-to-detect cancers earlier and fit into routine care.
Strong top line: GRAIL reported first-quarter revenue of $40.8 million, up 28% year over year, driven by 56,000-plus Galleri tests sold and a 37% rise in screening revenue.
Commercial momentum: Management said physician adoption, health-system engagement and digital health partnerships all continued to expand, with about 1,300 new prescribers added in the quarter.
Guidance held: Despite the beat, the company reiterated full-year revenue growth guidance of 22% to 32% and said it is still waiting to see how newer digital health partnerships scale.
Clinical catalyst: GRAIL is heading into ASCO with full data from NHS-Galleri and PATHFINDER 2, which management expects to further educate providers and customers.
FDA path: The FDA has accepted GRAIL’s PMA submission, and management said discussions with regulators have been constructive, but it would not speculate on whether an advisory committee will be held.
Access strategy: Epic integration, along with Quest and Athena, is positioned as a major workflow improvement for health systems and a key driver of second-half momentum.
Margins and cash: Gross profit improved as test volume rose and reprocessing costs fell, while the company ended the quarter with $823.1 million in cash.
